Goldman Sachs Group Inc Protalix Bio Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $580 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLX
# of Institutions
65Shares Held
5.8MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$973,3920.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$965,5200.0% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$507,8550.0% of portfolio
-
Gsa Capital Partners LLP London, X0401KShares$481,4920.03% of portfolio
-
Black Rock Inc. New York, NY333KShares$399,8050.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $59.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...